Single agent gemcitabine (gem) in metastatic renal cell carcinoma (mRCC).

被引：0
|
作者：
Hugec, V [1 ]
Koulova, L [1 ]
Garino, A [1 ]
Wiernik, PH [1 ]
Dutcher, JP [1 ]
机构：
[1] Our Lady Mercy Med Ctr, Bronx, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：452S / 452S
页数：1
相关论文
共 50 条
  • [41] Impact of early identification of brain metastases in metastatic renal cell carcinoma (mRCC)
    Parmar, Ambika
    Ghosh, Sunita
    Lalani, Aly-Khan A.
    Hansen, Aaron Richard
    Reaume, M. Neil
    Wood, Lori
    Basappa, Naveen S.
    Heng, Daniel Yick Chin
    Graham, Jeffrey
    Kollmannsberger, Christian K.
    Soulieres, Denis
    Breau, Rodney H.
    Tanguay, Simon
    Kapoor, Anil
    Pouliot, Frederic
    Bjarnason, Georg A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Understanding patient and provider preferences in management of metastatic renal cell carcinoma (mRCC)
    Yazdanpanah, Omid
    Benjamin, David Joseph
    Vosoughi, Elham
    Raad, Ali
    Popal, Medina
    Kongtim, Piyanuch
    Mar, Nataliya
    Rezazadeh, Arash
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Gut microbiome composition and response to sunitinib in metastatic renal cell carcinoma (mRCC).
    Gong, Jun
    Dizman, Nazli
    Poroyko, Valeriy
    Won, Haejung
    Bergerot, Cristiane Decat
    Bergerot, Paulo Gustavo
    Maia, Manuel C.
    Hsu, Joann
    Frankel, Paul Henry
    Jones, Jeremy
    Salgia, Ravi
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [44] Economic burden of adverse events in patients with metastatic renal cell carcinoma (mRCC).
    Hagiwara, May
    Borker, Rohit
    Oster, Gerry
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).
    Escudier, Bernard J.
    Iacovelli, Roberto
    Lanoy, Emilie
    Albiges, Laurence
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [46] Liver-directed therapy (LDT) for metastatic renal cell carcinoma (mRCC): Single center experience.
    Raychaudhuri, Ruben
    Bylow, Kathryn A.
    Lea, William
    Byun, John
    Zellmer, Timothy
    Burfeind, John D.
    Riese, Matthew John
    Kilari, Deepak
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [47] Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC)
    Buti, Sebastiano
    Brighenti, Matteo
    Bongiovanni, Cristiano
    Buzio, Carlo
    Chiesa, Matteo Dalla
    Alberici, Federico
    Passalacqua, Rodolfo
    JOURNAL OF IMMUNOTHERAPY, 2007, 30 (07) : 780 - 786
  • [48] ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features
    Haas, N.
    Manola, J.
    Pins, M.
    Liu, G.
    McDermott, D.
    Nanus, D.
    Heath, E.
    Wilding, G.
    Dutcher, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] A case of metastatic renal cell carcinoma treated effectively by gemcitabine and sunitinib
    Morizane, Shuichi
    Iwamoto, Hideto
    Yao, Akihisa
    Isoyama, Tadahiro
    Sejima, Takehiro
    Takenaka, Atsushi
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2012, 65 (04) : 227 - 229
  • [50] Efficacy and safety of apatinib monotherapy in metastatic renal cell carcinoma (mRCC) patients: A single-arm observational study
    Cui, Yan
    Cao, Yuxuan
    Cao, Muyang
    Chen, Xueting
    Liu, Guobin
    Chen, Hui
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (12) : 936.e1 - 936.e6
12345